Tweet
Canada Communicable Disease Report
Volume 37 ? ACS-5
September 2011
An Advisory Committee Statement (<ABBR title="Advisory Committee Statement">ACS</ABBR>). National Advisory Committee on Immunization (<ABBR title="National Advisory Committee on Immunization">NACI</ABBR>)<SUP>?</SUP>.
<!-- PDF Version
xx Pages - xx <abbr title="kilobyte">kb</abbr>
-->
Statement on Seasonal Influenza Vaccine for 2011?2012
Preamble
The National Advisory Committee on Immunization (<ABBR title="National Advisory Committee on Immunization">NACI</ABBR>) provides the Public Health Agency of Canada with ongoing and timely medical, scientific and public health advice relating to immunization and certain prophylaxis agents. The Public Health Agency of Canada (<ABBR title="Public Health Agency of Canada">PHAC</ABBR>) acknowledges that the advice and recommendations set out in this statement are based upon the best current available scientific knowledge and is disseminating this document for information purposes. People administering the vaccine should also be aware of the contents of the relevant product leaflet(s). Recommendations for use and other information set out herein may differ from that set out in the product monograph(s)/leaflet(s) of the Canadian manufacturer(s). Manufacturer(s) have sought approval of the vaccine(s) and provided evidence as to safety and efficacy only when it is used in accordance with the product monographs. <ABBR title="National Advisory Committee on Immunization">NACI</ABBR> members and liaison members conduct themselves within the context of the Public Health Agency of Canada's Policy on Conflict of Interest, including yearly declaration of potential conflict of interest.
IMPORTANT note regarding antiviral guidelines:
Antiviral recommendations are no longer under the purview of <ABBR title="National Advisory Committee on Immunization">NACI</ABBR>. A guidance document for the practitioner on the use of antiviral medication entitled ?The Use of Antiviral Drugs for Influenza: Guidance for Practitioners, 2010-11
(276 Kb, 49 pages)", has been developed by the Association of Medical Microbiology and Infectious Disease Canada (<ABBR title="Association of Medical Microbiology and Infectious Disease">AMMI</ABBR> Canada)
Full text:
Volume 37 ? ACS-5
September 2011
An Advisory Committee Statement (<ABBR title="Advisory Committee Statement">ACS</ABBR>). National Advisory Committee on Immunization (<ABBR title="National Advisory Committee on Immunization">NACI</ABBR>)<SUP>?</SUP>.
<!-- PDF Version
xx Pages - xx <abbr title="kilobyte">kb</abbr>
-->
Statement on Seasonal Influenza Vaccine for 2011?2012
Preamble
The National Advisory Committee on Immunization (<ABBR title="National Advisory Committee on Immunization">NACI</ABBR>) provides the Public Health Agency of Canada with ongoing and timely medical, scientific and public health advice relating to immunization and certain prophylaxis agents. The Public Health Agency of Canada (<ABBR title="Public Health Agency of Canada">PHAC</ABBR>) acknowledges that the advice and recommendations set out in this statement are based upon the best current available scientific knowledge and is disseminating this document for information purposes. People administering the vaccine should also be aware of the contents of the relevant product leaflet(s). Recommendations for use and other information set out herein may differ from that set out in the product monograph(s)/leaflet(s) of the Canadian manufacturer(s). Manufacturer(s) have sought approval of the vaccine(s) and provided evidence as to safety and efficacy only when it is used in accordance with the product monographs. <ABBR title="National Advisory Committee on Immunization">NACI</ABBR> members and liaison members conduct themselves within the context of the Public Health Agency of Canada's Policy on Conflict of Interest, including yearly declaration of potential conflict of interest.
IMPORTANT note regarding antiviral guidelines:
Antiviral recommendations are no longer under the purview of <ABBR title="National Advisory Committee on Immunization">NACI</ABBR>. A guidance document for the practitioner on the use of antiviral medication entitled ?The Use of Antiviral Drugs for Influenza: Guidance for Practitioners, 2010-11
(276 Kb, 49 pages)", has been developed by the Association of Medical Microbiology and Infectious Disease Canada (<ABBR title="Association of Medical Microbiology and Infectious Disease">AMMI</ABBR> Canada)Full text:
